The European Commission approved Vyloy (zolbetuximab) in combination with fluoropyrimidine- and platinum-containing chemotherapy for the first-line treatment of adult patients with locally advanced unresectable or metastatic human epidermal growth factor receptor 2-negative gastric or gastroesophageal junction adenocarcinoma whose tumors are claudin 18.2 positive.
Scientists face limitations in determining the results of drug effectiveness, as well as ensuring even distribution among all cancer cells because of the highly compact nature of tumors. Researchers are working to change that by giving chemotherapy drugs a kind of chemical “signal” to track them inside cells.
